Topotecan - study
PreclinicalSmall molecule
Topotecan - study is one of 10 small molecule programs targeting CLE. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in CLE
#DrugCompanyPhaseTrials
1Zytiga
Johnson & JohnsonPhase 3
Zuragard
ZZurex Pharma, Inc.
Phase 2
Keto Acid
UUniversity Hospital, Clermont-Ferrand
Phase 3
Brethine
SanofiPreclinical
Povidine-Iodine
MMidAtlantic Retina
Phase 2
Pharmacokinetics
PfizerPhase 1
Clenbuterol
UUniversity of Copenhagen
Preclinical
Triptorelin Acetate
IpsenPreclinical
Topotecan - study
HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Preclinical
Recombinant Hcg
UUniversitair Ziekenhuis Brussel
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
SCLC1 trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Topotecan Response and Toxicity in Patients With Small Cell Lung Cancer.
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Preclinical·NCT07145333·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Topotecan - study. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details